1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Blood and immune system conditions
  5. Blood and bone marrow cancers

Guidance on the use of imatinib for chronic myeloid leukaemia

Technology appraisal guidance [TA70] Published: 22 October 2003 Last updated: 21 January 2016

  • Guidance
  • Tools and resources
  • Information for the public
  • History
  • Overview
  • 1 Guidance
  • 2 Clinical need and practice
  • 3 The technology
  • 4 Evidence and interpretation
  • 5 Recommendations for further research
  • 6 Implications for the NHS
  • 7 Implementation and audit
  • 8 Related guidance
  • 9 Review of guidance
  • Appendix A. Appraisal Committee members and NICE project team
  • Appendix B. Sources of evidence considered by the Committee
  • Appendix C. Detail on criteria for audit of the use of imatinib for chronic myeloid leukaemia
Download guidance (PDF)

Guidance

  • Next

8 Related guidance

8 Related guidance

The Institute issued guidance on the use of imatinib for people with CML in the chronic phase after failure of IFN-α, in the accelerated phase and in blast crisis in October 2002, which is now replaced by this current guidance.


  • Next